NVSEF News and Press, Novartis Ag Basel Akt

2024-07-26 11:48:00 ET Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032...

2024-07-20 03:50:03 ET Summary The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core o...

2024-07-19 10:15:54 ET Summary On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology fr...

2024-07-18 14:19:35 ET Summary MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is ...

2024-07-18 12:49:03 ET Novartis AG (NVS) Q2 2024 Earnings Conference Call July 18, 2024, 08:00 AM ET Company Participants Sloan Simpson - Head of IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Emily Field - Barclays Floren...

2024-07-18 02:41:22 ET More on Novartis: Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis beats top-line and bottom-line estimates; raises FY24 core operating income out...

2024-07-18 01:48:21 ET More on Novartis: Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis intends to implement merger squeeze-out of MorphoSys minority shareholders Re...

2024-07-17 11:20:00 ET Summary During the quarter, we sold our position in Novartis and invested the proceeds in Roche. We decided to sell Novartis to fund the purchase of what we believe is a more optimal investment in Roche. Considering Roche's ~4% dividend yield and our pro...

2024-07-17 11:05:00 ET Summary For the second quarter of 2024, Aristotle Capital’s International Equity Composite posted a total return of -0.85% gross of fees (-0.96% net of fees). During the quarter, we sold our position in Novartis and invested the proceeds in Roche. ...

2024-07-15 10:09:03 ET Summary Novartis AG will report second quarter results this week. The company should report another strong quarter, with growth led by key products such as Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio. I expect a modest revenue and EPS beat, with NV...